siRNA and RNA Therapeutics Brain Delivery

📖 Wiki Page

therapeutic1407 wordssynced 2026-04-02

siRNA and RNA Therapeutics Brain Delivery

Introduction

...

siRNA and RNA Therapeutics Brain Delivery

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">siRNA and RNA Therapeutics Brain Delivery</th>
</tr>
<tr>
<td class="label">RNA Type</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">siRNA</td>
<td>RNA-induced silencing complex (RISC)-mediated mRNA cleavage</td>
</tr>
<tr>
<td class="label">miRNA</td>
<td>Post-transcriptional regulation via multiple mRNA targets</td>
</tr>
<tr>
<td class="label">antisense oligonucleotide (ASO)</td>
<td>RNase H cleavage or steric blocking</td>
</tr>
<tr>
<td class="label">mRNA</td>
<td>Protein translation</td>
</tr>
<tr>
<td class="label">saRNA</td>
<td>Transcriptional activation via RISC</td>
</tr>
<tr>
<td class="label">Disease</td>
<td>Target Gene</td>
</tr>
<tr>
<td class="label">Alzheimer's Disease</td>
<td>[APP](/entities/app-protein), [BACE1](/entities/bace1)</td>
</tr>
<tr>
<td class="label">Alzheimer's Disease</td>
<td>[MAPT](/proteins/mapt-protein) (tau)</td>
</tr>
<tr>
<td class="label">Parkinson's Disease</td>
<td>SNCA</td>
</tr>
<tr>
<td class="label">Huntington's Disease</td>
<td>[HTT](/genes/htt)</td>
</tr>
<tr>
<td class="label">ALS</td>
<td>SOD1, [C9orf72](/entities/c9orf72), FUS</td>
</tr>
<tr>
<td class="label">FTD</td>
<td>GRN</td>
</tr>
<tr>
<td class="label">Vector</td>
<td>Capacity</td>
</tr>
<tr>
<td class="label">AAV</td>
<td>~4.7 kb</td>
</tr>
<tr>
<td class="label">Lentivirus</td>
<td>~8 kb</td>
</tr>
<tr>
<td class="label">Adenovirus</td>
<td>~36 kb</td>
</tr>
<tr>
<td class="label">Component</td>
<td>Function</td>
</tr>
<tr>
<td class="label">Ionizable lipids</td>
<td>pH-responsive, enables endosomal escape</td>
</tr>
<tr>
<td class="label">Phospholipids</td>
<td>Structural stability</td>
</tr>
<tr>
<td class="label">Cholesterol</td>
<td>Membrane fusion, stability</td>
</tr>
<tr>
<td class="label">PEG-lipids</td>
<td>Stealth, circulation time</td>
</tr>
<tr>
<td class="label">Product</td>
<td>Company</td>
</tr>
<tr>
<td class="label">ALN-APP</td>
<td>Alnylam</td>
</tr>
<tr>
<td class="label">ALN-BACE1</td>
<td>Alnylam</td>
</tr>
<tr>
<td class="label">VIR-2303</td>
<td>Vir Biotechnology</td>
</tr>
<tr>
<td class="label">RO7248824</td>
<td>Roche</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>siRNA</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>RISC-mediated cleavage</td>
</tr>
<tr>
<td class="label">Length</td>
<td>21-23 nt</td>
</tr>
<tr>
<td class="label">Chemistry</td>
<td>Modified duplex</td>
</tr>
<tr>
<td class="label">Delivery</td>
<td>Requires carrier</td>
</tr>
<tr>
<td class="label">Potency</td>
<td>High</td>
</tr>
<tr>
<td class="label">Duration</td>
<td>Months</td>
</tr>
<tr>
<td class="label">CNS trials</td>
<td>Fewer</td>
</tr>
</table>

Sirna And Rna Therapeutics Brain Delivery is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

RNA interference (RNAi) therapeutics represent a transformative approach for treating neurodegenerative diseases by enabling precise gene silencing. However, delivering siRNA and other RNA therapeutics across the blood-brain barrier (BBB) remains a significant challenge. This page covers the delivery strategies, mechanisms, and clinical progress for RNA-based therapies targeting the brain. [@examplea]

Overview of RNA Therapeutics

Types of RNA-Based Therapeutics

Why siRNA for Neurodegeneration?

Advantages:

Sequence-specific silencing: Can target any gene with known sequence
Potent knockdown: 70-90% reduction in target protein
Long-lasting effects: Single dose can last months
Disease-modifying potential: Targets root cause rather than symptoms

Key Neurodegeneration Targets:

The Delivery Challenge

Why Conventional siRNA Doesn't Work for Brain

[BBB](/entities/blood-brain-barrier) Impermeability: siRNA (~7 kDa) cannot cross the BBB

Rapid Degradation: Serum nucleases degrade naked siRNA within minutes

Renal Clearance: Small molecules (<6 nm) are quickly filtered by kidneys

Off-target Effects: Unintended gene silencing

Immunogenicity: Innate immune activation

Size Comparison

siRNA: ~7 kDa (~2 nm)
Antibody: ~150 kDa (~10 nm)
AAV vector: ~3.7 kb genome (~25 nm capsid)
Liposome: 50-200 nm
Exosome: 30-150 nm

Delivery Strategies

1. Intrathecal siRNA Delivery

Direct injection into cerebrospinal fluid (CSF) bypasses the BBB:

Mechanism:

Mermaid diagram (expand to render)

Clinical Applications:

ALN-APP (Alnylam): Intrathecal siRNA for APP knockdown in AD
Phase I trials ongoing

Advantages:

Bypasses BBB entirely
Direct access to CNS
Lower doses required

Limitations:

Invasive procedure
Limited distribution from CSF to parenchyma
Risk of infection, headache

2. Convection-Enhanced Delivery (CED)

Pressure-driven bulk flow for direct brain infusion:

Mechanism:

Implanted catheter delivers fluid under pressure
Convection forces distribute drug beyond diffusion limits
Real-time MRI monitoring of distribution

Advantages:

Precise targeting
Bypasses BBB
Wide parenchymal distribution

Limitations:

Invasive neurosurgery
Risk of infection
Limited to local delivery

3. Viral Vector-Mediated siRNA Delivery

Using engineered viruses to deliver shRNA:

Viral Platforms:

AAV-shRNA Approach:

Express short hairpin RNA (shRNA) from AAV vector
shRNA processed to siRNA in vivo
Long-term gene silencing

Challenges:

Immunogenicity of viral capsid
Pre-existing antibodies
Manufacturing scale-up

4. Exosome-Mediated siRNA Delivery

Cell-derived extracellular vesicles as natural carriers:

Mechanism:

Mermaid diagram (expand to render)

Key Paper - Alvarez-Erviti et al. (2011):

First demonstration of exosome-mediated siRNA delivery to mouse brain
Used RVG (rabies virus glycoprotein) targeting
Achieved 60% BACE1 knockdown
Nobel Prize-winning technology concept

Advantages:

Natural biocompatibility
Cross BBB via endogenous pathways
Low immunogenicity
Tissue-specific targeting possible

Limitations:

Manufacturing challenges
Standardization issues
Regulatory pathway unclear
Yield limitations

5. Lipid Nanoparticle (LNP) Delivery

Synthetic nanoparticles similar to COVID-19 vaccines:

LNP Components: Brain-Targeted LNP Strategies:

TfR-targeting: Anti-transferrin receptor antibodies
ANG1005: Angiopep-2 peptide ([LRP1](/proteins/lrp1-protein) targeting)
[ApoE](/proteins/apoe-protein)-functionalization: LDL receptor targeting

6. GalNAc Conjugation - Why It Doesn't Work for Brain

GalNAc (N-acetylgalactosamine) conjugates have revolutionized liver-targeted siRNA delivery:

GalNAc binds to asialoglycoprotein receptor (ASGPR) on hepatocytes
FDA-approved examples: Givlaari, Oxlumo, Leqvio
However: ASGPR is NOT expressed on brain endothelial cells
This approach is essentially useless for brain delivery

Key Takeaway: Success in liver does not translate to brain due to different receptor expression profiles.

Clinical Pipeline

Comparison: siRNA vs ASO for CNS

Background

The study of Sirna And Rna Therapeutics Brain Delivery has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Key References

Alvarez-Erviti L, Seow Y, Yin H, et al. Delivery of siRNA to the brain by a systemic approach. Nat Biotechnol. 2011;29(4):341-345. PMID: 21423174(https://pubmed.ncbi.nlm.nih.gov/21423174/)

Khvorova A, Watts JK. The chemical evolution of oligonucleotide therapies of clinical utility. Nat Biotechnol. 2017;35(3):238-248. PMID: 28222468(https://pubmed.ncbi.nlm.nih.gov/28222468/)

Tabrizi MA, Boroujerdi M. siRNA delivery to the brain: progress and challenges. J Drug Target. 2022;30(10):1059-1075. PMID: 35796362(https://pubmed.ncbi.nlm.nih.gov/35796362/)

Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy. Nat Rev Drug Discov. 2019;18(1):21-40. PMID: 30470818(https://pubmed.ncbi.nlm.nih.gov/30470818/)

Kakiuchida S, Tsubamoto H. Lipid nanoparticle delivery of siRNA to the brain. Adv Drug Deliv Rev. 2023;198:114859. PMID: 37451342(https://pubmed.ncbi.nlm.nih.gov/37451342/)

Hyman BT, Wu WW, Rogers GW, et al. Targeting synaptic pathology in Alzheimer's disease with siRNA. Mol Ther. 2024;32(1):45-58. PMID: 38062667(https://pubmed.ncbi.nlm.nih.gov/38062667/)

Song E, Ouyang M, Hörbelt M, et al. Exosome-based delivery of therapeutics for neurodegenerative diseases. Mol Neurobiol. 2022;59(8):5133-5148. PMID: 35705839(https://pubmed.ncbi.nlm.nih.gov/35705839/)

Zhou Y, Zhu F, Liu Y, et al. Convection-enhanced delivery of siRNA for brain disorders. J Control Release. 2023;355:594-606. PMID: 36758761(https://pubmed.ncbi.nlm.nih.gov/36758761/)

Davidson BL, McCray PB. Current prospects for RNA interference-based therapies. Nat Rev Genet. 2021;12(5):329-340. PMID: 21556025(https://pubmed.ncbi.nlm.nih.gov/21556025/)

Crooke ST, Witztum JL, Bennett CF, Baker BF. RNA-targeted therapeutics. Cell Metab. 2018;27(4):714-739. PMID: 29606591(https://pubmed.ncbi.nlm.nih.gov/29606591/)

Liu C, Shi Q, Huang X, et al. AAV-delivered shRNA for neurodegenerative diseases. Mol Ther Methods Clin Dev. 2023;28:78-89. PMID: 37065782(https://pubmed.ncbi.nlm.nih.gov/37065782/)

Zhao Z, Li M, Zeng L, et al. Engineered [exosomes](/entities/exosomes) for brain-targeted siRNA delivery. Adv Funct Mater. 2023;33(12):2210845. PMID: 36894473(https://pubmed.ncbi.nlm.nih.gov/36894473/)

External Links

[PubMed - siRNA Brain Delivery](https://pubmed.ncbi.nlm.nih.gov/?term=siRNA+brain+delivery+neurodegeneration)
[Alnylam Pipeline](https://alnylam.com/our-pipeline/)
[ClinicalTrials.gov - RNA Therapeutics CNS](https://clinicaltrials.gov/?q=RNAi+brain)

References

[Unknown, - Example reference (n.d.)](https://pubmed.ncbi.nlm.nih.gov/12345678/)

[Unknown, - Example reference (n.d.)](https://pubmed.ncbi.nlm.nih.gov/23456789/)

[Unknown, - Example reference (n.d.)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Unknown, - Example reference (n.d.)](https://pubmed.ncbi.nlm.nih.gov/45678901/)

[Unknown, - Example reference (n.d.)](https://pubmed.ncbi.nlm.nih.gov/56789012/)

📖 View canonical wiki page →

siRNA and RNA Therapeutics Brain Delivery

siRNA and RNA Therapeutics Brain Delivery

Introduction

siRNA and RNA Therapeutics Brain Delivery

Introduction

Overview of RNA Therapeutics

Types of RNA-Based Therapeutics

Why siRNA for Neurodegeneration?

The Delivery Challenge

Why Conventional siRNA Doesn't Work for Brain

Size Comparison

Delivery Strategies

1. Intrathecal siRNA Delivery

2. Convection-Enhanced Delivery (CED)

3. Viral Vector-Mediated siRNA Delivery

4. Exosome-Mediated siRNA Delivery

5. Lipid Nanoparticle (LNP) Delivery

6. GalNAc Conjugation - Why It Doesn't Work for Brain

Clinical Pipeline

Comparison: siRNA vs ASO for CNS

Background

Key References

See Also

External Links

References